Literature DB >> 20674944

Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.

Tomoyuki Hishida1, Kanji Nagai, Tetsuya Mitsudomi, Kohei Yokoi, Haruhiko Kondo, Hirohisa Horinouchi, Hirohiko Akiyama, Takeshi Nagayasu, Masahiro Tsuboi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20674944     DOI： 10.1016/j.jtcvs.2010.06.035

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN： 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  22 in total

1.  Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.

Authors:  Kohei Hashimoto; Hirohisa Horinouchi; Takashi Ohtsuka; Mitsutomo Kohno; Yotaro Izumi; Yuichiro Hayashi; Hiroaki Nomori
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-06-12

Review 2.  Current Topics on Salvage Thoracic Surgery in Patients with Primary Lung Cancer.

Authors:  Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-03-04       Impact factor: 1.520

3.  The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

Authors:  Ryo Ko; Hirotsugu Kenmotsu; Yasushi Hisamatsu; Hiroaki Akamatsu; Shota Omori; Kazuhisa Nakashima; Takuya Oyakawa; Kazushige Wakuda; Takehito Shukuya; Akira Ono; Hisao Imai; Tetsuhiko Taira; Tateaki Naito; Haruyasu Murakami; Keita Mori; Masahiro Endo; Yasuhisa Ohde; Kazuhisa Takahashi; Toshiaki Takahashi
Journal:  Int J Clin Oncol       Date:  2014-10-25       Impact factor: 3.402

4.  The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.

Authors:  Masaki Goto; Masahito Naito; Koichi Saruwatari; Kakeru Hisakane; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Shogo Nomura; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Kohei Yokoi; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-17       Impact factor: 4.553

Review 5.  Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.

Authors:  Haoran Zhai; Wenzhao Zhong; Xuening Yang; Yi-Long Wu
Journal:  Transl Lung Cancer Res       Date:  2015-02

6.  Long-Term Outcomes of Lobectomy for Non-Small Cell Lung Cancer After Definitive Radiation Treatment.

Authors:  Chi-Fu Jeffrey Yang; R Ryan Meyerhoff; Sarah J Stephens; Terry Singhapricha; Christopher B Toomey; Kevin L Anderson; Chris Kelsey; David Harpole; Thomas A D'Amico; Mark F Berry
Journal:  Ann Thorac Surg       Date:  2015-04-15       Impact factor: 4.330

7.  Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.

Authors:  Tomoyuki Hishida; Junji Yoshida; Keiju Aokage; Kanji Nagai; Masahiro Tsuboi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-12-16

8.  Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy.

Authors:  Ye Ning; Minwei Bao; Xiaoxia Yan; Dong Xie; Gening Jiang
Journal:  Ann Transl Med       Date:  2018-10

9.  Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case.

Authors:  Kaoru Kaseda; Ken-ichi Watanabe; Keisuke Asakura; Akio Kazama
Journal:  World J Surg Oncol       Date:  2015-02-22       Impact factor: 2.754

10.  Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.

Authors:  Kuo Li; Xiaonian Cao; Bo Ai; Han Xiao; Quanfu Huang; Zheng Zhang; Qian Chu; Li Zhang; Xiaofang Dai; Yongde Liao
Journal:  Thorac Cancer       Date:  2021-06-15       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.